134 related articles for article (PubMed ID: 37248652)
1. Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.
Kwok TSH; Kuriya B; Hawker G; Li P; Choy G; Widdifield J
Arthritis Care Res (Hoboken); 2023 Dec; 75(12):2463-2471. PubMed ID: 37248652
[TBL] [Abstract][Full Text] [Related]
2. Adherence and Treat-to-Target Benchmarks in Older Adults With Gout Initiating Urate-Lowering Therapy in Ontario, Canada: A Population-Based Study.
Kwok TSH; Kuriya B; Hawker G; Eder L; Li P; Choy G; Widdifield J
Arthritis Care Res (Hoboken); 2024 Jun; ():. PubMed ID: 38831665
[TBL] [Abstract][Full Text] [Related]
3. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
Juraschek SP; Kovell LC; Miller ER; Gelber AC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
[TBL] [Abstract][Full Text] [Related]
4. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
5. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
[TBL] [Abstract][Full Text] [Related]
7. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
Quilisadio JEC; Salido EO; Penserga EG
Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
[TBL] [Abstract][Full Text] [Related]
9. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
[TBL] [Abstract][Full Text] [Related]
10. Serum urate goal attainment and associated factors in Chinese gout patients.
Guo G; Dong C; Yin R; Yang Y; Zhao R; Wang Y; Guo J; Zhou W; Lu G
Psychol Health Med; 2020 Sep; 25(8):931-939. PubMed ID: 31870173
[TBL] [Abstract][Full Text] [Related]
11. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
[TBL] [Abstract][Full Text] [Related]
12. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
13. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
16. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
[TBL] [Abstract][Full Text] [Related]
17. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661
[TBL] [Abstract][Full Text] [Related]
18. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
[No Abstract] [Full Text] [Related]
19. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
Levy GD; Rashid N; Niu F; Cheetham TC
J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
[TBL] [Abstract][Full Text] [Related]
20. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
